Clinical trial
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic…
NCT00033540 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00033540 |
|---|---|
| Title | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma |
| Official title | A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients With Unresectable or Metastatic Gallbladder or Cholangiocarcinoma |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extrahepatic Bile Duct Cancer, Gallbladder Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gemcitabine hydrochloride |
| Enrollment | 57 |
| Start date | Sep 1, 2003 |
| Primary completion | Apr 1, 2008 |
| Completion | Jul 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 12, 2017 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: